Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX209 for Irritability in Autism Spectrum Disorders
NCT00846547Phase 2Completed
- Sponsor
- Seaside Therapeutics
- Start
- Feb 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arbaclofen in Autism Spectrum Disorder (ASD), sponsored by Seaside Therapeutics. Started Feb 2009; status: completed.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00846547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846547.